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Deficiency of methylthioadenosine phosphorylase (MTAP) supports melanoma develop-
ment and progression through accumulation of its substrate 5’-methylthioadenosine (MTA),
which leads amongst others to a constitutive inhibition of protein arginine methyltrans-
ferases (PRMTs) and activation of the transcription factor AP-1 via the receptor ADORA2B.
Genetic association studies have also suggested that genetic polymorphism inMTAPmay
modulate the risk of melanoma. Here, we investigated the only globally common non-syn-
onymous single nucleotide polymorphism (SNP) reported to date forMTAP. The SNP
rs7023954 is located in exon 3 (c.166G>A), and leads to the conservative substitution of
one branched-chain amino acid residue (valine) for another (isoleucine) at position 56
(p.Val56Ile). Whereas genotype frequencies in normal and primary melanoma tissues or
cell lines were in Hardy-Weinberg equilibrium based on cDNA amplicon sequencing, a
marked (P = 0.00019) deviation was observed in metastatic melanoma tissues and cell
lines due to a deficit of heterozygotes. Enzyme assays conducted on the co-dominantly
expressed alleles revealed no difference in the conversion rate of MTA to adenine and 5-
methylthioribose-1-phosphate, indicating that this known enzymatic activity does not modu-
late the tumor suppressive function of MTAP.
Introduction
The incidence of malignant melanoma is steadily increasing [1]. Melanoma is a highly invasive
cancer characterized by early metastasis and rapid development of resistance to current thera-
peutic approaches [2]. In the past years, great progress has been made in our understanding of
the molecular pathobiology of melanoma. In particular, the identification of driver mutations
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in genes encoding proteins that play a role in the MAPK pathway, such as BRAF, NRAS, and
MEK (MAPK kinase), has spurred the development of novel targeted treatment strategies
[3,4]. Another gene that has received increasing interest is methylthioadenosine phosphorylase
(MTAP). It catalyzes the first step in the methionine salvage pathway by phosphorylating S-
methyl-5'-thioadenosine (MTA), a major byproduct of the polyamine metabolism, to adenine
and 5-methylthioribose-1-phosphate [5,6]. Many tumors lack expression ofMTAP, due either
to its loss at the 9p21 locus or to hypermethylation of its promoter region [5–8].MTAP defi-
ciency results in the accumulation of MTA [9,10]. High intracellular levels of MTA have been
shown to cause deregulation of protein arginine methyltransferases (PRMTs) [8,11]. Further,
extracellular MTA affects cellular signaling [8,12] and proliferation [13], not only of cancer
cells but also of stromal cells including lymphocytes and fibroblasts, via induction of mela-
noma-relevant genes such as the growth factors VEGF and bFGF and the metalloproteinases
MMP9 and MMP14 [7]. This MTA-based effect could not be observed in melanocytes. Fur-
ther, it could be shown, that MTA treatment leads to an activation of the transcription factor
AP-1 [7], which is highly active in melanoma and influences the expression of a variety of regu-
lators of cell mechanisms involved in melanoma development and metastasis [14]. Activation
of AP-1 is modulated by the binding of MTA to the adenosine receptor A2B [12].
In recent years, numerous single nucleotide polymorphisms (SNPs) have been reported for
theMTAP locus on chromosome 9p21 to dbSNP, including 120 missense polymorphisms, all
but one of which are rare or show high population specificity. The only exception is rs7023954,
which is located in exon 3 (c.166G>A) ofMTAP and leads to the exchange of valine for isoleu-
cine (p.Val56Ile) [6]. It is found worldwide with a minor allele frequency of 0.3882 and an aver-
age observed heterozygosity of 0.475. Spurred by reports of an association of theMTAP locus
with melanoma risk [15,16], this study aimed at investigating the frequency of rs7023954 geno-
types in normal skin as well as primary and metastatic melanoma tissues and cell lines. Further,
we studied allele-specific expression of MTAP at the protein level in trypsin-digested whole-
cell extracts using liquid chromatography-mass spectrometry and stable isotope-labeled pro-
teotypic peptides specific for either allele. Finally, we measured enzyme activity of the alleles
both in a rabbit reticulocyte lysate translation system as well as in transiently and stably trans-
fected cells.
Material and Methods
Cell lines, culture conditions and tissue samples
Melanoma cell lines Mel Juso, Mel Ho, Mel Ei, Mel Wei, 501Mel, SkMel3, SkMel28, Mel Im,
Mel Ju, A375, HMB2, and NHEMs were described in detail previously [6,8,17]. Briefly, cell
lines Mel Juso (DSMZ: ACC74), Mel Ho (ATTC: ACC62), Mel Wei, and Mel Ei were derived
from primary cutaneous melanomas; Mel Im, Mel Ju, 501Mel, A375 (ATTC: CRL-1619),
SkMel3 (ATTC: HTB-69), SkMel28 (ATTC: HTB-72), and HMB2 were derived from metasta-
ses of malignant melanomas. Melanoma cell lines WM35, WM793, WM1366, WM3211 (pri-
mary cutaneous melanomas) and WM9 andWM293A (metastases of malignant melanoma)
were a kind gift by Dr. M. Herlyn (Wistar Institute, Philadelphia, PA, USA) and cultivated as
described in Tu2% medium [18]. NHEMs were derived from neonatal skin. Isolation and culti-
vation of NHEMs were described previously [19]. Generation of stably transfected Mel Juso
clones (Mock N, KSNV-01 and KWT-04) was achieved by culturing the cells one day after
transfection in selection medium, containing 0.6 mg/mL G418 (Sigma-Aldrich, Taufkirchen,
Germany). After 14 days of selection, individual G418-resistant colonies were sub-cloned.
Expression ofMTAP in these clones was determined by qRT-PCR andWestern Blot. NHDF
cells were obtained from Promocell (Heidelberg, Germany). Primary human dermal fibroblasts
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(NHDF1-6) were cultured as described previously [20]. Cells were maintained in DMEM or
RPMI1640 (Sigma-Aldrich, Deisenhofen, Germany) supplemented with penicillin (400 U/
mL), streptomycin (50 μg/mL), and 10% fetal bovine serum (FBS) (all from Sigma-Aldrich).
The cell lines Mel Juso, Mel Ei, Mel Ho, Mel Wei, Mel Im, HMB2, A375, Mel Ju, 501Mel,
SKMel3 and SKMel28 were incubated in a humidified atmosphere containing 8% CO2 at 37°C.
Cell lines from the Wistar Institute were cultured at 5% CO2 and 37°C. Cells were split at a 1:3
to 1:5 ratio every 4 days.
Tissue specimens
Tissue specimens of snap-frozen melanoma primary tumors (PT60, PT62, PT71, PT87, PT93,
PT97, PT104, and TB148) and melanoma metastases (TB43, TB50, TB80, TB90, TB91, TB95,
TB101, TB135 and TB147) with clear-cut pathological classification were obtained from the tis-
sue collection of the Institute of Pathology (University of Regensburg, Germany). Sampling
and handling of patient material were carried out in accordance with the ethical principles of
the Declaration of Helsinki. Use of human tissue material (NL3, NH14, NL146 TB88, TB89,
NH118, NH119, NH120, TB121, TB122; TB60, TB62, TB71 TB87, TB93, TB97, TB104, TB148;
TB43, TB50, TB80, TB90, TB91, TB95, TB101, TB135, and TB147 obtained from the Depart-
ment of Dermatology, University Hospital of Regensburg, Germany) had been approved by
the local ethics committee of the University of Regensburg (application number 09/11 and 03/
151).
RNA isolation and reverse transcription
Total cellular RNA was isolated from cultured cells using the E.Z.N.A1 Total RNA Kit I
(Omega Bio-Tek/ VWR, Darmstadt, Germany) according to the manufacturer’s instructions.
cDNAs were generated from 500 ng total RNA using SuperScript II Reverse Transcriptase Kit
(Invitrogen, Groningen, Netherlands) as described previously [21].
Amplification and sequencing ofMTAP-Exon 3
For PCR amplification of exon 3 ofMTAP, 1 μL cDNA (extracted from tissue or cell lines, or
2 μL genomic DNA (extracted from tissue or cell lines) were added to 0.5 μL of forward and
reverse primers (MTAP-for89: 5’-GCCCACTGCAGATTCCTTTC-3’; MTAP-rev416: 5’-
GGTCTCATAGTGGTCCTGTC-3’; each 20 μM), 5 μL PCR reaction buffer (10x), 0.5 μL dNTP
mix (each 10 mM), and 0.5 μL (2.5 Units) FastStart Taq DNA Polymerase dNTPack (Roche,
Mannheim, Germany) in a total reaction volume of 50 μL. The following PCR program was
used: 5 min at 95°C (initial denaturation); 60 s at 95°C (denaturation); 30 s at 61°C (annealing),
30 s at 72°C (elongation), repeated 35 times. PCR products were evaluated by gel electrophore-
sis using a 1.5% agarose gel. Before sequencing, amplicons were purified by precipitation with
30% PEG-8000 (Sigma-Aldrich) to remove unincorporated primers and dNTPs. Purified PCR
products were given to GeneArt AG/ Thermo Fisher Scientific Inc. (Regensburg, Germany) as
complete mix of 10 ng per 100 bp of PCR-product-length and 10 μM Primer MTAP-Ex3for
5’-CATGCATGCAGCCATCTG-3’ or MTAP-Ex3rev 5’- CGTCAGACCTGTATCTTTAC-3’
for Sanger sequencing.
Analysis of gene expression by qRT-PCR
Quantitative real time-PCR analysis ofMTAP was performed using specific primers (MTAP-
for2: 5’-GCGAACATCTGGGCTTTG-3’; MTAPrev2: 5’-GCACCGGAGTCCTAGCTTC-3’)
and a LightCycler1 480 (Roche, Mannheim, Germany) as described previously [22]. ß-Actin
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(ß-Actin for: 50-CTACGTGGCCCTGGACTTCGAGC-30; ß-Actin rev: 5’-GATGGAGCCGCC
GATCCACACGG-30) was used as a housekeeping gene for normalization. The annealing and
melting temperatures were optimized for each primer set. All experiments were repeated at
least three times.
Transfection vector
The coding sequence ofMTAP was cloned into pCMX-PL1. By specific PCR-reaction using
Primer MTAP89for and MTAP987rev the coding sequence of MTAP was amplified [6]. Using
the TA Cloning1 Kit (Invitrogen, Groningen, Netherlands), the PCR product was cloned into
the TOPO-Cloning Vector according to the manufacturer’s instructions. Full-length (CDS)
MTAP-cDNA was then cloned into the pCMX-PL1 via KpnI/EcoRI (NEB, Frankfurt, Ger-
many) generating the expression constructs MTAP-56V and MTAP-56I. The respective clones
were confirmed by sequencing using MTAPfor89 primer.
Transfection experiments
For re-expression ofMTAP, 2x105 Mel Juso cells were seeded into 6-well plates and transfected
with 0.5 μg of the expression construct (MTAP-56V or MTAP-56I) or pCMX-PL1 vector
using Lipofectamine1 LTX reagent (Life Technologies, Darmstadt, Germany) according to the
manufacturer’s instructions. Twenty-four hours after transfection the medium was changed
and the cells were incubated for another 24 h, before supernatant was collected and stored at
-80°C until metabolite analysis. Transfected cells were split for mRNA and protein isolation, as
well as for metabolite analysis (1x106 cells). All transfections were repeated at least three times.
In vitro translation in a rabbit reticulocyte lysate translation system
Using the TNT1Quick Coupled Transcription/Translation System (IVT; Promega, Madison,
WI, USA) according to the manufacturer’s instructions, pCMX-PL1, MTAP-56V and MTAP-
56I were used for recombinant protein expression. The master mix containing all supplements
and 1 μg of either vector was incubated at 30°C for 90 min. The translation efficiency of each
sample was determined by Western Blot analysis. The recombinant proteins were stored at
-20°C until use.
Western Blot
For Western Blot analysis, 5 μL of in vitro translation mix or 40 μg of RIPA-cell lysates were
loaded per lane, and performed as described previously using anti-MTAP antibody (0.5 μg/mL
ab55517, Abcam, Cambridge, UK) and anti-ß-actin (1:5000; Sigma-Aldrich) [8]. All Western
Blots were repeated three times. Protein bands in western blots were quantified using computer
based colorimetric quantification analysis (freeware: ImageJ v1.33 downloaded from the NIH
website (http://rsb.info.nih.gov/ij)).
Enzyme kinetics
For analyzing MTAP-enzyme-kinetic, the in vitro translation mix with the recombinant pro-
teins or the control, respectively, was diluted ¼ in PBS. Subsequently, 1 μL of the dilution was
added to MTA (10 μM) in 20 μL PBS and incubated at 37°C for defined periods of time (30 s to
30 min). The reaction was stopped by adding 600 μL of 80%MeOH, snap-frozen and stored at
-80°C until measurement. All samples were prepared in triplicates and the MTAP-enzyme-
kinetic was repeated three times.
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MTA extraction and analysis by liquid chromatography-electrospray
ionization-tandemmass spectrometry (LC-ESI-MS/MS)
For analysis of MTA in cell culture medium, cells were cultured for 24 h. Subsequently, super-
natant was collected, centrifuged (1200 rpm), snap-frozen, and stored at -80°C. For determina-
tion of intracellular MTA, cells were washed with PBS and harvested by incubation in a
solution containing 0.05% (w/v) trypsin and 0.02% (w/v) EDTA. Trypsinization was stopped
after 2 min with cell culture medium. After centrifugation (1200 rpm, 4 min), the supernatant
was removed, the cell pellet was washed with PBS buffer and the cell number was determined
by counting the trypsinized cells. The cell pellet was snap-frozen and stored at -80°C. Samples
were further processed as described previously [9].
Analysis of MTAP-56V and MTAP-56I by MS
Cell pellets were lysed by sonification in 300 μL of 100 mM ammonium bicarbonate buffer (pH
7.8) for 10 min. After centrifugation protein concentrations were determined via UV absorp-
tion at 280 nm using a NanoDrop2000 system (NanoDrop Instruments, Wilmington, DE,
USA). Fifty μg of protein per sample was used for digestion using the RapidACN protocol [23].
Two μg of the resulting peptide mixtures were supplemented with 100 fmol each of the stable
isotope-labeled peptides NVDCVLLAR(+10) and NVDCILLAR(+10) and subjected to
MRM-HR analysis on a TripleTOF5600+ mass spectrometer (SCIEX GmbH, Darmstadt, Ger-
many) coupled to a Ultimate3000 nano-HPLC (Dionex GmbH, Idstein, Germany). A 28-min-
gradient from 4%-40% B (A: 0.1% formic acid; B: 0.1% formic acid in acetonitrile) was used for
separation on a 75 μm I.D., 25 cm long C18-column (Acclaim PepMap, 3 μm, 100 Ǻ, flow rate
300 μL/min) with precolumn concentration (Acclaim PepMap, 100 μm I.D., 2 cm, 5 μm, 100
Ǻ, flow rate 5 μL/min). MS/MS-spectra were acquired for 0.5 s each and quantification was
accomplished using the Skyline software (MacLean B, et al., Skyline: an open source document
editor for creating and analyzing targeted proteomics experiments, Bioinformatics, 2010)
based on the transitions from the doubly charged precursors to the singly charged fragment
ions y5, y6 and y7.
Statistical analysis
Results are expressed as either mean ± S.E.M. (range) or percent. Comparison between groups
was performed using one-way ANOVA with Bonferroni post-hoc test. A p-value<0.05 was
considered statistically significant (ns: not significant). All calculations were performed
using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). Testing of
rs7023954 genotypes for Hardy-Weinberg equilibrium (HWE) was performed at https://www.
cog-genomics.org/software/stats using Fisher’s exact test and Lancaster’s mid-P correction for
better control over type I error rates [24]. Both genotypic and allelic odds ratios were calculated
based on genotype and allele counts, respectively, for rs7023954 in control and primary mela-
noma samples [25]. The null hypothesis of no association with disease was tested by means of a
χ2 test for independence of the rows and columns of 2x2 and 2x3 contingency tables.
Results
Genotyping ofMTAP rs7023954
The non-synonymousMTAP SNP rs7023954 (c.G166A, p.Val56Ile, GenBank accession num-
bers XM 027613 and NM 00D2451) was genotyped by Sanger sequencing of exon 3, which had
been PCR amplified from reverse transcribedMTAP transcripts isolated from normal skin as
well as primary and metastatic melanoma cell lines and tissues (Fig 1, S1 Table). In both,
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normal skin and primary melanoma cell lines and tissue, the distribution of genotypes did not
deviate significantly from HWE. In contrast, a highly significant (P = 0.00019) deviation from
HWE, due to a deficit of heterozygotes, was observed in metastatic tumor tissue and cell lines.
However, limiting the analysis to metastatic melanoma tissues only, no significant deviation
(P = 0.0719) from HWE could be detected. Finally, testing for a genetic association between
rs7023954 and primary melanoma using a χ2 test, no significant association could be found
regardless whether the frequency of alleles or genotypes was considered.
Quantitation ofMTAP rs7023954 allelic expression at the protein level
To confirm expression of theMTAP rs7023954 alleles at the protein level, six cell lines homo-
zygous for either the A- (Mel Im, Mel Ho and A375) or the G-allele (WM793, WM1366 and
WM293A) and a heterozygous fibroblast cell line (3F0379) were analyzed by LC-MS/MS using
allele-specific stable isotope-labeled proteotypic peptides as internal standards for accurate
quantitation (Table 1). We determined isoleucine at position 56 in all samples with the AA
genotype and valine in all samples with the GG genotype, respectively, while the heterozygous
Fig 1. Determination ofMTAP rs7023954 in cell lines and tissue samples. The non-synonymousMTAP
SNP c.G166A was genotyped by sequencing of cDNA that had been produced from total RNA extracted from
both normal as well as primary (prim.) and metastatic (met.) melanoma cell lines and tissues. Distribution of
the genotypes AA, AG, and GG is shown. A detailed description of the genotypes of the samples investigated
is given in S1 Table.
doi:10.1371/journal.pone.0160348.g001
Table 1. Confirmation of cDNA genotype by liquid chromatography-tandemmass spectrometry
(LC-MS/MS) based protein expression analysis. Sole expression of the 56I-allele was observed in mela-
noma cell lines Mel Im, Mel Ho, and A375, whereas the 56V-allele was detected exclusively in WM793,
WM1366, andWM293A. In the fibroblast cell line 3F0379, both alleles were co-expressed equally.
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cell line 3F0379 showed co-dominant expression of both alleles. Expression levels ranged from
20 fmol/mg protein for Mel Ho to 2800 fmol/mg protein for A375. In the other melanoma cell
lines, expression differed far less, ranging from 180 to 320 fmol/mg protein. The low level of
MTAP protein expression detected in Mel Ho agreed with Western blotting performed previ-
ously (Behrmann et al., 2003). In the heterozygous cell line 3F0379, alleles were expressed at 60
fmol/mg protein each.
Enzyme kinetics of in vitro-translated MTAP
Recombinant MTAP protein with either 56V or 56I was expressed by in vitro transcription/
translation (IVT). The translation efficiency of pCMX-PL1 (control vector), MTAP-56V and
MTAP-56I was monitored by Western Blot analysis (Fig 2A; S1 Fig). Enzyme kinetic assays
showed no difference in the rate of catabolism of MTA between the alleles (Fig 2B).
Enzyme kinetics of MTAP in transiently and stably transfected cells
Reaction rates of the twoMTAP alleles were also measured in cell culture. To that end, the mel-
anoma cell line Mel Juso, which did not express any MTAP protein detectable by LC-MS/MS,
was transfected with control (pCMX-PL1) vector, MTAP- 56I or MTAP-56V expression con-
struct, respectively. Successful transfection was confirmed by qRT-PCR and Western Blot (Fig
3A). Both MTAP-56I and MTAP-56V transfected cells showed a similarly strong reduction in
intracellular MTA levels compared to the control (Fig 3B; S2 Fig).
To quantify the differences between MTAP variants in Mel Juso after long-time re-expres-
sion of MTAP-56V andMTAP-56I, stably transfected clones were generated and analyzed in
the same manner. MTAP expression was confirmed at the RNA and protein level (Fig 4A). The
cells were analyzed for intracellular MTA by LC-MS/MS (Fig 4B; S3 Fig). Again, a significant
reduction in MTA concentration was detected in MTAP re-expressing cell clones compared to
control. The reduction in intracellular MTA concentration was again similar for the alleles.
Discussion
The chromosomal locus 9p21 has been implicated in the pathogenesis of cutaneous malignant
melanoma [26,27]. Several studies have revealed a link between 9p21 and pigmentation
[27,28]. Increased pigmentation in metastatic melanoma tissue is associated with both a signifi-
cant shorter overall survival (OS) and progression free survival (PFS) [29] as well as a poor
response to radiotherapy [30]. The locus also harbors, aside fromMTAP, the type I interferon
(IFN) gene cluster, the two cyclin-dependent kinase inhibitors CDKN2A (encoding p16INK4a
and p14ARF) and CDKN2B (encoding p15INK4b), and a long intergenic noncoding RNA, desig-
nated antisense noncoding RNA in the INK4 locus (ANRIL), which has been shown to regulate
CDKN2A/B by epigenetic mechanisms [31].
Genome-wide association studies (GWAS) have identified a number of loci predicting
nevus count, including the 9p21 locus, which is also significantly associated with melanoma
risk [15]. Recent studies reported a significant association of theMTAP SNPs rs7023329
(intron 2) and rs10811629 (intron 5) with melanoma incidence and number of melanocytic
nevi [28]. Further, theMTAP polymorphism rs10757257G in intron 1 was found to be signifi-
cantly associated with melanoma risk in adults and, in particular, with superficial spreading
and nodular melanoma subtypes [16].
To date, the non-synonymous SNP rs7023954 in exon 3 of theMTAP gene, which results in
a conservative substitution of a branched-chain amino acid residue at position 56 for another,
has not been linked to melanoma development. Here, we genotyped rs7023954 in both primary
and metastatic melanoma cell lines and tissues and compared the genotype and allele counts
MTAP SNP in Melanoma
PLOSONE | DOI:10.1371/journal.pone.0160348 August 1, 2016 7 / 13
observed to those in normal skin tissue and cell lines. We further confirmed in the fibroblast
cell line 3F0379, which is heterozygous for rs7023954, the co-dominant expression of the alleles
at the protein level by LC-MS/MS using allele-specific stable-isotope labeled peptides as inter-
nal standards for accurate quantitation. While the genotype frequencies observed in normal
and primary melanoma samples adhered to those expected under the Hardy-Weinberg
assumption, a significant deviation from HWE was found in metastatic melanoma samples
due to a deficit of heterozygotes. However, considering metastatic melanoma tissue only, no
significant deviation from HWE could be detected. This is not an uncommon finding in
Fig 2. Enzyme kinetics of both in vitro-translated MTAP variants. (A) Western Blot for determination of MTAP
expression by in vitro transcription/translation of the pCMX-PL1 (1.0) control plasmid and the expression constructs for
MTAP-56I (2.56-fold increased) and MTAP-56V (2.28-fold increased). Densitometric quantification revealed increased
MTAP amount. The original Western blot is shown in S1 Fig. (B) Analysis of the metabolic activity of the in vitro-
translated products by liquid chromatography–tandemmass spectrometry. Catalytic rates of IVT-MTAP-56I and
IVT-MTAP-56V were corrected for the rate of the control, which was set at 1.
doi:10.1371/journal.pone.0160348.g002
MTAP SNP in Melanoma
PLOSONE | DOI:10.1371/journal.pone.0160348 August 1, 2016 8 / 13
comparative high-resolution surveys of genome-wide chromosomal abnormalities in estab-
lished cell lines and primary human tumors [32]. Moreover, in contrast to previous papers that
had observed homozygous deletions of theMTAP locus in 3 out of 11 [33] and 1 out 9 investi-
gated melanoma cell lines [6], respectively, no evidence of a diallelic deletion of theMTAP
locus was found here. This supports our previous finding, that loss or reduction of MTAP
expression in melanoma is more often the result of hypermethylation of the promoter region
than chromosomal deletion of theMTAP locus [6].
Fig 3. Effect of both MTAP variants in transiently cells.Quantification of MTAP expression at the mRNA (A) and protein level (B) in the melanoma
cell line Mel Juso after transient transfection of expression constructs for MTAP-56I and MTAP-56V or control plasmid (pCMX-PL1). The original
Western blot is shown in S2 Fig. (C) Analysis of intracellular MTA levels in the transiently transfected Mel Juso cells.
doi:10.1371/journal.pone.0160348.g003
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Tests of genetic association performed on observed allele counts in normal and primary
melanoma samples showed a positive, albeit not significant association ofMTAP rs7023954G
(OR 1.746, 95% CI = 0.6928–4.4006) with melanoma. It cannot be excluded that the lack of sig-
nificance is a consequence of the small sample size studied and the resulting lack of statistical
power. As a matter of fact, the odds ratio of 1.746 observed forMTAP rs7023954G is quite
similar to that reported forMTAP rs10757257G and melanoma risk in adults (OR = 1.32,
95% CI = 1.14–1.54). This led us to investigate whether the G allele might differ in enzymatic
Fig 4. Enzyme kinetics of both MTAP variants in stably transfected cells.Quantification of MTAP expression at the mRNA (A) and protein level
(B) in the melanoma cell line Mel Juso after stable transfection of control plasmid (pCMX-PL1) or expression constructs for MTAP-56I and MTAP-
56V. The original Western blot is shown in S3 Fig. (C) Analysis of intracellular MTA levels in the stably transfected Mel Juso cell clones.
doi:10.1371/journal.pone.0160348.g004
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activity from the A allele. We cloned both alleles and expressed them using both a rabbit reticu-
locyte lysate translation system as well as transient and stable transfection of anMTAP-null
melanoma cell line. In all three systems, enzyme kinetics of the alleles did not differ signifi-
cantly, indicating that a difference in catabolism of MTA is unlikely to contribute to melanoma
development and progression. This concords with a recently published study that found a cata-
lytically inactive version ofMTAP, which was introduced into HT1080 fibrosarcoma cells, to
be fully capable of reversing various tumor phenotypes such as soft agar colony formation and
increased migration and metalloproteinase production [34].
Conclusion
The absence of a difference in the rate of catabolism of MTA to adenine and 5-methylthiori-
bose-1-phosphate between the alleles of the only common amino acid substitution polymor-
phism described to date forMTAP lends further support to the notion, that the tumor
suppressive function ofMTAP is independent of its known enzymatic activity.
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